MoonLake Immunotherapeutics (MLTX)
Develops sonelokimab for inflammatory diseases including hidradenitis suppurativa and psoriatic arthritis.
Something off on this page? Send us feedback.
Develops sonelokimab, an investigational Nanobody that inhibits IL-17A and IL-17F, for inflammatory diseases. Its work centers on hidradenitis suppurativa and psoriatic arthritis, with additional programs in adolescent HS, palmoplantar pustulosis, and axial spondyloarthritis.
Develops sonelokimab, an investigational Nanobody designed to inhibit IL-17A and IL-17F. The licensed global-rights asset is the central program, with earlier clinical-data lineage at Ablynx and Merck KGaA.
Clinical work centers on hidradenitis suppurativa and psoriatic arthritis. The portfolio also includes adolescent HS, palmoplantar pustulosis, and axial spondyloarthritis; adult HS is studied in the global VELA-1 and VELA-2 trials, and PsA in the IZAR program.
Operations are headquartered in Zug, Switzerland, while adult HS is studied globally. Progress depends on trial outcomes, regulatory review, and any future approval of the investigational medicine.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 13, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $45 | Target: $50 |
| May 11, 2026 | H.C. Wainwright | Target | Target: $32 | Target: $45 |
| Mar 23, 2026 | Wolfe Research | Upgrade | ||
| Mar 19, 2026 | Rothschild & Co | Upgrade | ||
| Feb 24, 2026 | Oppenheimer | Reiterate | Rating: —Target: $30 | Target: $35 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $537.0M · Total debt $101.5M · Total assets $573.9M · Shareholders' equity $428.2M
- Revenue
- $0
- Operating income
- −$61.7M
- Net income
- −$61.8M
No dividends on record.
| Institutions | ≈ 85.64% | 72.88M shares | |
|---|---|---|---|
| 187 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 3.50% | 2.98M shares | |
| 3 holders · as of Jul 29, 2026 | |||
| Other | ≈ 10.86% | 9.24M shares | |
| remainder | |||
85.11M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BVF Inc/ILInstitution | 18.80% | 16.00M | as of Jun 30, 2026 |
Biotechnology Value Fund L PInstitution | 9.76% | 8.30M | filed Jun 29, 2026 |
Deep Track Capital, LPInstitution | 8.22% | 7.00M | as of Jun 30, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 5.03% | 4.28M | as of Jun 30, 2026 |
D. E. Shaw & Co., Inc.Institution | 3.95% | 3.37M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 27, 2026 | Kristian Reich | officer: Chief Scientific Officer | −1,100 | $20.00 |
| Jul 22, 2026 | Kristian Reich | officer: Chief Scientific Officer | −2,448 | $20.00 |
| Jul 21, 2026 | Kristian Reich | officer: Chief Scientific Officer | −50,000 | $20.02 |
| Jul 20, 2026 | Kristian Reich | officer: Chief Scientific Officer | −43,700 | $20.09 |
| Jul 15, 2026 | Kristian Reich | officer: Chief Scientific Officer | −16,105 | $20.01 |
- United Community Banks
Dual IL-17A/F biologic approved for HS and PsA
- Novartis (ADR)
IL-17A biologic approved for HS, PsA, and axSpA
- AbbVie
TNF blocker with U.S. labels in HS and PsA
- Johnson & Johnson
IL-23 biologic approved for active PsA
- Eli Lilly
IL-17A biologic approved for PsA and axial SpA
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MoonLake Immunotherapeutics | $12.63 | −5.58% | $1.13B | — | — | — | — |
| United Community Banks | $33.76 | −1.27% | $4.09B | 11.2 | 10.7 | 2.6 | +9.8% |
| Novartis (ADR) | $142.63 | +0.95% | $268.53B | 21.3 | 15.2 | 4.8 | +0.9% |
| AbbVie | $264.77 | −0.17% | $468.77B | 74.8 | 17.4 | 7.3 | +10.2% |
| Johnson & Johnson | $268.34 | −0.32% | $648.72B | 31.2 | 22.6 | 6.6 | +6.6% |
| Eli Lilly | $1,152.13 | −1.54% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| Median | 31.2 | 17.4 | 6.6 | +9.8% |